Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 622 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sedentary Control Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Computer-based Brief Intervention for Perinatal Substance Abuse

NCT00685074
View directory record Official record
Conditions
Substance Abuse
Interventions
Computer-based Motivational Interviewing, Time control
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2011 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Not applicable Interventional

Attention Control Training for PTSD in Children

NCT03348540
View directory record Official record
Conditions
PTSD
Interventions
Attention Control Training, Comparison Task
Behavioral
Lead sponsor
Creighton University
Other
Eligibility
7 Years to 15 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

NCT02636699
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250mcg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Daily Activity Study of Health: Increasing Physical Activity in Aging

NCT04315363
View directory record Official record
Conditions
Aging
Interventions
Motivational MRI and Behavioral Intervention, Control MRI and Behavioral Intervention
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
60 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 19, 2026, 2:52 AM EDT
Recruiting Early Phase 1 Interventional

HCQ in Resectable Localized Prostate Cancer

NCT06408298
View directory record Official record
Conditions
Resectable Localized Prostate Cancer
Interventions
Hydroxychloroquine Sulfate 400Mg Tab, Placebo
Drug
Lead sponsor
Lionel.D.Lewis, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

NCT02128958
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
CF102, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

NCT05290493
View directory record Official record
Conditions
22q11 Deletion Syndrome
Interventions
NB-001, Placebo
Drug · Other
Lead sponsor
Nobias Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 19, 2026, 2:52 AM EDT
Terminated Phase 4 Interventional

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

NCT04443608
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer Powder for Oral Suspension [Veltassa], Placebo
Drug
Lead sponsor
Comprehensive Research Associates
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 19, 2026, 2:52 AM EDT
Active, not recruiting Phase 2 Interventional

Ibudilast for Treating Alcohol Use Disorder

NCT05414240
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Alcoholism
Interventions
Ibudilast, Medical management, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Social Exergaming for Healthy Weight in Adolescent Girls

NCT02003963
View directory record Official record
Conditions
Obesity and Physical Inactivity in Adolescents
Interventions
Klub Kinect
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 19, 2026, 2:52 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Mobile App to Improve 24-Hour Movement Guideline Adherence in Preschoolers

NCT06667661
View directory record Official record
Conditions
Healthy, 24-Hour Movement Guidelines, Feasibility Studies, Sleep, Physical Activity, Screen Time, Sedentary Behaviors, Motor Skills, Cognition, Parent-Child Relations, Mobile Application, Health Education, Child Development
Interventions
Shining Star mHealth App
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
3 Years to 4 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Augmenting Language Therapy for Aphasia: Levodopa

NCT01429077
View directory record Official record
Conditions
Nonfluent Aphasia, Stroke
Interventions
levodopa/carbidopa, Placebo comparator
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 25, 2013 · Synced Oct 19, 2026, 2:52 AM EDT
Completed No phase listed Observational

Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis

NCT00894712
View directory record Official record
Conditions
Breast Cancer, Dermatitis
Interventions
Sulforaphane-containing broccoli sprout extracts (active agent), Vehicle (inactive control)
Other · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life

NCT05523180
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Non-cystic Fibrosis Bronchiectasis
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
ResBiotic Nutrition, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • The Villages, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT04629170
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
SYNB8802, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Ashwagandha Extract (Capsule KSM-66 300 mg) on Sexual Health in Healthy Women

NCT05831241
View directory record Official record
Conditions
Sexual Health
Interventions
Ashwagandha, Placebo
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
18 Years to 55 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Phase 4 Interventional Results available

Brain Aging and Treatment Response in Geriatric Depression

NCT01902004
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Depression
Interventions
Escitalopram, Memantine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 19, 2026, 2:52 AM EDT
Terminated Phase 3 Interventional

Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

NCT01098981
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Transcranial ultrasound as an adjunctive therapy to tPA, Standard of care tPA therapy for acute ischemic stroke
Device · Drug
Lead sponsor
Cerevast Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Home Offerings Via the Mealtime Environment (HOME) Plus

NCT01538615
View directory record Official record
Conditions
Obesity
Interventions
HOME Plus intervention
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 19, 2026, 2:52 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 2:52 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of PEMF Therapy in Treatment of Post-operative Pain Following Total Knee Arthroplasty

NCT02211534
View directory record Official record
Conditions
Post-Operative Pain Following Total Knee Arthroplasty
Interventions
Pulsed Electromagnetic Field Device (Provant), Sham Pulsed Electromagnetic Field Device
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • El Cajon, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 19, 2026, 2:52 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

NCT03819881
View directory record Official record
Conditions
Atopic Immunoglobulin E-Mediated Allergic Disorder
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
2 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Stockton, California • Tustin, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 19, 2026, 2:52 AM EDT